Intravenous or subcutaneous natalizumab in patients with relapsing –remitting multiple sclerosis: investigation on efficiency and savings—the EASIER study
ConclusionsSC natalizumab administration will consistently reduce consumption of patient and HCP times per procedure and associated costs. (Source: Journal of Neurology)
Source: Journal of Neurology - September 16, 2023 Category: Neurology Source Type: research
Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosis
Conclusions
Older age is associated with a lower prevalence and degree of focal inflammatory disease activity in treated and untreated RRMS. Our findings inform the design of RCTs, and suggest that patient age should be taken into consideration when deciding on immunomodulatory treatment in RRMS. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - September 14, 2023 Category: Neurosurgery Authors: Strijbis, E. M., Coerver, E., Mostert, J., van Kempen, Z. L. E., Killestein, J., Comtois, J., Repovic, P., Bowen, J. D., Cutter, G., Koch, M. Tags: Multiple sclerosis Source Type: research
Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis
Relapsing-remitting multiple sclerosis (RRMS) is the most common phenotype of multiple sclerosis (MS), and its active stage is characterized by active T2 lesions with or without gadolinium (Gd) enhancement on ... (Source: BMC Neurology)
Source: BMC Neurology - August 29, 2023 Category: Neurology Authors: Takahiko Saida, Qi Hao, Michihiro Kanda and Yumiko Tani Tags: Research Source Type: research
Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada
Conclusion: Results highlight the value of a high-efficacy therapy such as ofatumumab as initial treatment (i.e., first-line) in newly diagnosed relapsing-remitting multiple sclerosis patients with active disease.PMID:37606897 | DOI:10.57264/cer-2022-0175 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - August 22, 2023 Category: General Medicine Authors: Virender Bhan Fraser Clift Moogeh Baharnoori Kimberly Thomas Barkha P Patel Fran çois Blanchette Nicholas Adlard Umakanth Vudumula Kapil Gudala Nikkita Dutta Daniel Grima Souka ïna Mouallif Fatine Farhane Source Type: research
Natalizumab-immunogenicity evaluation in patients with infusion related events or disease exacerbations
ConclusionReal-world evidence shows that the presence of ANA is behind an important percentage of patients treated with natalizumab that experience IRE, as well as DE but in a lower degree. These findings support the need to systematically evaluate ANA towards a personalized management of these patients to avoid undesired complications. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - August 22, 2023 Category: Allergy & Immunology Source Type: research
Fertility, pregnancy and childbirth in women with multiple sclerosis: a population-based study from 2018 to 2020
Conclusions
Fertility rate in women with MS remains below the general population. Family planning and subsequent DMT decisions should aim to achieve successful pregnancy, delivery and breastfeeding outcomes, while controlling disease activity. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - August 14, 2023 Category: Neurosurgery Authors: Moccia, M., Affinito, G., Fumo, M. G., Giordana, R., Di Gennaro, M., Mercogliano, M., Carotenuto, A., Petracca, M., Lanzillo, R., Triassi, M., Brescia Morra, V., Palladino, R. Tags: Multiple sclerosis Source Type: research
Disease Evolution in Women With Highly Active MS Who Suspended Natalizumab During Pregnancy vs Rituximab/Ocrelizumab Before Conception
Discussion
Suspending RTX/OCR in the year before conception in women with highly active MS was associated with no disease reactivation during and after pregnancy. As previously reported, stopping NTZ at the end of the first trimester was associated with disease reactivation. In women receiving NTZ who are planning pregnancy, a bridge to RTX/OCR for pregnancy or continuing NTZ until week 34 are both reasonable clinical decisions. The RTX/OCR option is more comfortable for women and reduces the exposure of infants to monoclonal antibodies. (Source: Neurology Neuroimmunology and Neuroinflammation)
Source: Neurology Neuroimmunology and Neuroinflammation - August 7, 2023 Category: Neurology Authors: Demortiere, S., Maarouf, A., Rico, A., Boutiere, C., Hilezian, F., Durozard, P., Pelletier, J., Audoin, B. Tags: Multiple sclerosis Research Article Source Type: research
On a 5-year-old girl with multiple sclerosis treated with natalizumab
(Source: Neurological Sciences)
Source: Neurological Sciences - July 14, 2023 Category: Neurology Source Type: research
[Translated Article] Disease-modifying treatments for patients with multiple sclerosis in Spain
CONCLUSIONS: We have described the disease-modifying treatment of patients with multiple sclerosis seen in Spanish pharmacy services and characterized concomitant treatments, the prevalence of polypharmacy, interactions, and their complexity.PMID:37394376 | DOI:10.1016/j.farma.2023.05.005 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - July 2, 2023 Category: Drugs & Pharmacology Authors: Alejandro Santiago P érez Santos Esteban Casado Miriam Álvarez Payero Ángel Escolano Pueyo Ángel Guillermo Arévalo Bernabé N úria Padullés Zamora Pilar Diaz Ruiz Ana Mar ía López González Source Type: research
[Translated Article] Disease-modifying treatments for patients with multiple sclerosis in Spain
CONCLUSIONS: We have described the disease-modifying treatment of patients with multiple sclerosis seen in Spanish pharmacy services and characterized concomitant treatments, the prevalence of polypharmacy, interactions, and their complexity.PMID:37394376 | DOI:10.1016/j.farma.2023.05.005 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - July 2, 2023 Category: Drugs & Pharmacology Authors: Alejandro Santiago P érez Santos Esteban Casado Miriam Álvarez Payero Ángel Escolano Pueyo Ángel Guillermo Arévalo Bernabé N úria Padullés Zamora Pilar Diaz Ruiz Ana Mar ía López González Source Type: research
[Translated Article] Disease-modifying treatments for patients with multiple sclerosis in Spain
CONCLUSIONS: We have described the disease-modifying treatment of patients with multiple sclerosis seen in Spanish pharmacy services and characterized concomitant treatments, the prevalence of polypharmacy, interactions, and their complexity.PMID:37394376 | DOI:10.1016/j.farma.2023.05.005 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - July 2, 2023 Category: Drugs & Pharmacology Authors: Alejandro Santiago P érez Santos Esteban Casado Miriam Álvarez Payero Ángel Escolano Pueyo Ángel Guillermo Arévalo Bernabé N úria Padullés Zamora Pilar Diaz Ruiz Ana Mar ía López González Source Type: research
[Translated Article] Disease-modifying treatments for patients with multiple sclerosis in Spain
CONCLUSIONS: We have described the disease-modifying treatment of patients with multiple sclerosis seen in Spanish pharmacy services and characterized concomitant treatments, the prevalence of polypharmacy, interactions, and their complexity.PMID:37394376 | DOI:10.1016/j.farma.2023.05.005 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - July 2, 2023 Category: Drugs & Pharmacology Authors: Alejandro Santiago P érez Santos Esteban Casado Miriam Álvarez Payero Ángel Escolano Pueyo Ángel Guillermo Arévalo Bernabé N úria Padullés Zamora Pilar Diaz Ruiz Ana Mar ía López González Source Type: research
A safety review of current monoclonal antibodies used to treat multiple sclerosis
This article reviews the literature on the use of mAbs for the treatment of MS, including their mechanisms of action, clinical trial data, safety profiles, and long-term outcomes. The review focuses on the three main categories of mAbs used in MS: alemtuzumab, natalizumab, and anti-CD20 drugs. A literature search was conducted using relevant keywords and guidelines and reports from regulatory agencies were reviewed. The search covered studies published from inception to 31 December 2022. The article also discusses the potential risks and benefits of these therapies, including their effects on infection rates, malignancies,...
Source: Expert Opinion on Drug Safety - June 14, 2023 Category: Drugs & Pharmacology Authors: Gloria Dalla Costa Giancarlo Comi Source Type: research
